DNMT3A and neoplasm: A recent study showed that SYC-52221 and EPZ004777 inhibitors that target DOT1L, decrease tumor cell proliferation and induce cell apoptosis, cycle arrest, and terminal differentiation in DNMT3A mutant cell lines in a dose- and time-dependent manner (46).